LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

Inclusion Criteria: * Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists * Measurable or evaluable disease * 18 and over * ECOG 0-2 * Hematopoietic * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 9 g/dL (erythrocyte transfusions allowed) * Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * ALT and AST no greater than 2.5 times ULN (5 times ULN if liver metastases present) * Renal * Creatinine clearance at least 50 mL/min * Potassium at least 3.4 mEq/L * Calcium at least 8.4 mg/dL * Magnesium at least 1.2 mEq/L * Cardiovascular * QTc interval no greater than 450 msec in males * QTc interval no greater than 470 msec in females * No other electrocardiogram abnormalities * Able to swallow capsules * Negative pregnancy test * Fertile patients must use effective contraception during and for 3-6 months after study * Endocrine therapy * At least 4 weeks since prior anticancer hormonal therapy * At least 6 weeks since prior bicalutamide * At least 4 weeks since prior flutamide or nilutamide * Concurrent luteinizing hormone-releasing hormone analog therapy (e.g., leuprolide or goserelin) allowed for patients with prostate cancer if started before study entry * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin). * Radiotherapy * At least 4 weeks since prior radiotherapy * At least 2 weeks since prior palliative radiotherapy * Recovered from prior therapy * Other * At least 4 weeks since prior investigational anticancer therapy * At least 4 weeks since other prior anticancer therapy * At least 30 days since prior experimental drugs Exclusion Criteria: * known untreated or symptomatic CNS metastases * concurrent hematologic malignancies * gastrointestinal disorder that would interfere with oral drug absorption * serious concurrent systemic disorder * compliance issues that would preclude study * geographical conditions that would preclude study * active infection * prior hypersensitivity to any component of study drugs * pregnant or nursing * concurrent immunotherapy * concurrent routine filgrastim (G-CSF) * other concurrent chemotherapy * other concurrent hormonal therapy * concurrent radiotherapy (including palliative therapy) * other concurrent experimental medications * other concurrent anticancer therapy